New Releases from NCBI BookshelfQuizartinib (Vanflyta): Therapeutic area: Acute myeloid leukemia: Reimbursement Review [Internet].Quizartinib (Vanflyta): Therapeutic area: Acute myeloid leukemia: Reimbursement Review [Internet].
Post Content
The Formulary Management Expert Committee (FMEC) recommends that ibrutinib in combination with immunochemotherapy with or without autologous stem cell transplant
Canada’s Drug Agency (CDA-AMC) recommends that Voranigo be reimbursed by public drug plans for patients aged 12 years and older
For women with chronic or gestational hypertension who remain well, early term birth (at 37–38 weeks’ gestation) may reduce maternal
Several existing systematic reviews have examined the use of ketamine in the prehospital setting for acute pain, sedation, and RSI
Women who use drugs during the perinatal period often have complex health and social care needs. Their infants can experience
Despite high rates of adolescent mental health problems, there are few effective school-based interventions to address this. Whole-school interventions offer
Optimising comfort and ability to communicate for mechanically ventilated intensive care unit patients is a priority for clinicians, intensive care